Physician profile
Anton Juncaj
NPI 1649831314
$2,310.71
in general payments reported to CMS, 2019-2025
35 companies · $928 in 2025
The $928 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.21 · 2022: $134 · 2023: $440 · 2024: $784 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097 · Education: $56.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.52 |
| Education | $56.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $548.06 | 2022-2025 | |
| Genentech USA, INC. | $224.57 | 2023-2025 | Phesgo, Tecentriq, Lunsumio |
| Adaptive Biotechnologies Corporation | $182.71 | 2025 | Clonoseq |
| Astrazeneca Pharmaceuticals LP | $145.98 | 2023-2025 | Imfinzi, Tagrisso, Lynparza |
| Merck Sharp & Dohme LLC | $133.49 | 2023-2025 | Keytruda, Keytruda Qlex, Welireg |
| Janssen Biotech, INC. | $131.26 | 2022-2025 | Tecvayli, Talvey, Darzalex |
| Aveo Pharmaceuticals, INC. | $103.85 | 2023-2025 | Fotivda |
| Astellas Pharma US INC | $82.25 | 2025 | Vyloy, Xtandi, Xospata |
| Beigene USA, INC. | $71.30 | 2023-2025 | Brukinsa, Tevimbra |
| E.R. Squibb & Sons, L.L.C. | $61.97 | 2024 | Opdivo |
| Abbvie INC. | $52.14 | 2024-2025 | |
| Eisai INC. | $48.28 | 2023-2025 | |
| Amgen INC. | $38.33 | 2022-2023 | Blincyto, Kyprolis |
| Legend Biotech USA INC. | $35.71 | 2025 | Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $33.84 | 2024 | Iclusig |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $32.13 | 2023-2025 | Qinlock, Tgct |
| Geron Corporation | $31.65 | 2025 | Rytelo |
| Foundation Medicine, INC. | $29.09 | 2022-2023 | |
| Coherus Oncology, INC. | $27.43 | 2025 | Loqtorzi |
| Genmab U.S., INC. | $25.79 | 2024 | Epkinly |
| Boston Scientific Corporation | $24.21 | 2021 | |
| Genzyme Corporation | $22.50 | 2025 | |
| Glaxosmithkline, LLC. | $21.59 | 2025 | Jemperli, Zejula |
| Blueprint Medicines Corporation | $19.93 | 2025 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $19.82 | 2022 | |
| Rigel Pharmaceuticals, INC. | $19.52 | 2024 | Rezlidhia, Tavalisse |
| Pharmacyclics LLC, An Abbvie Company | $18.95 | 2023 | Imbruvica |
| Servier Pharmaceuticals LLC | $18.72 | 2024 | |
| Apellis Pharmaceuticals, INC. | $16.58 | 2024 | Empaveli |
| Incyte Corporation | $16.47 | 2024 | Jakafi |
| Novo Nordisk INC | $15.93 | 2023 | Novoeight, Rebinyn, Novoseven |
| Pharmacosmos Therapeutics INC. | $15.21 | 2023 | Monoferric |
| Lilly USA, LLC | $14.41 | 2024 | Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $13.92 | 2022 | |
| Pfizer INC. | $13.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anton Juncaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.